Tempo Bioscience Expands Human Liver Models for Toxicity Evaluation and Disease Modeling

SAN FRANCISCO, CA —Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following...

Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development

Oct 19, 2022

SAN FRANCISCO, CA —Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived...

We are Recruiting – Multiple Positions

Mar 10, 2022

Technical Alliance Manager (TAM) PhD level scientist with 0-2 years biotech or pharmaceutical industry experience We are looking for a skilled Technical Alliance Manager to join our team. The...

Top10 Biotech Startups – 2021

Oct 14, 2021

Tempo Bioscience is featured as the Cover Story in the 2021 Top10 Biotech Startups by Pharma Tech Outlook. Click here for the digital issue.

Tempo Bioscience Expands Patient-Relevant iPSC-Derived Cell Models

Apr 10, 2019

SAN FRANCISCO, CA —Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived...